← Back to directory

David Nutt

Researcher Next ID · RN-031921

Researcher · Medicine

Imperial Valley College

Imperial, United Kingdom

Accepting doctoral researchersFunding unknown
Works count
1,192
Citation count
52,204
H-index
110
i10-index
564

Research interests

Medicine
Neuroscience
Psychology
Neurotransmitter Receptor Influence on Behavior
Neuroscience and Neuropharmacology Research
Treatment of Major Depression
Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Psychedelics and Drug Studies

Publications

  • Increased global integration in the brain after psilocybin therapy for depression

    Nature Medicine · 2022 · 10.1038/s41591-022-01744-z

  • Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies

    Acta Psychiatrica Scandinavica · 2020 · 10.1111/acps.13249

  • Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

    The Lancet Psychiatry · 2016 · https://doi.org/10.1016/s2215-0366(16)30065-7

  • Increased Global Functional Connectivity Correlates with LSD-Induced Ego Dissolution

    Current Biology · 2016 · 10.1016/j.cub.2016.02.010

  • Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition

    The World Journal of Biological Psychiatry · 2016 · https://doi.org/10.1080/15622975.2016.1190867

  • The dopamine theory of addiction: 40 years of highs and lows

    Nature reviews. Neuroscience · 2015 · 10.1038/nrn3939

  • Factors influencing success of clinical genome sequencing across a broad spectrum of disorders

    Nature Genetics · 2015 · https://doi.org/10.1038/ng.3304

  • Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

    Journal of Psychopharmacology · 2014 · https://doi.org/10.1177/0269881114525674

  • Estimating the Harms of Nicotine-Containing Products Using the MCDA Approach

    European Addiction Research · 2014 · 10.1159/000360220

  • Homological scaffolds of brain functional networks

    Journal of The Royal Society Interface · 2014 · 10.1098/rsif.2014.0873

  • Amphetamine, past and present – a pharmacological and clinical perspective

    Journal of Psychopharmacology · 2013 · 10.1177/0269881113482532

  • Broadband Cortical Desynchronization Underlies the Human Psychedelic State

    Journal of Neuroscience · 2013 · 10.1523/jneurosci.2063-13.2013

  • GABA system dysfunction in autism and related disorders: From synapse to symptoms

    Neuroscience & Biobehavioral Reviews · 2012 · 10.1016/j.neubiorev.2012.07.005

  • Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

    Proceedings of the National Academy of Sciences · 2012 · https://doi.org/10.1073/pnas.1119598109

  • Drug harms in the UK: a multicriteria decision analysis

    The Lancet · 2010 · https://doi.org/10.1016/s0140-6736(10)61462-6

  • Relationship of neurotransmitters to the symptoms of major depressive disorder.

    PubMed · 2008

  • Sleep disorders as core symptoms of depression

    Dialogues in Clinical Neuroscience · 2008 · 10.31887/dcns.2008.10.3/dnutt

  • Development of a rational scale to assess the harm of drugs of potential misuse

    The Lancet · 2007 · https://doi.org/10.1016/s0140-6736(07)60464-4

  • Tryptophan metabolism in the central nervous system: medical implications

    Expert Reviews in Molecular Medicine · 2006 · 10.1017/s1462399406000068

  • The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

    Journal of Psychopharmacology · 2006 · 10.1177/0269881106069938

  • Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function

    Trends in Pharmacological Sciences · 2006 · https://doi.org/10.1016/j.tips.2006.06.005

  • Role of GABA in anxiety and depression

    Depression and Anxiety · 2006 · 10.1002/da.20262

  • Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

    Journal of Psychopharmacology · 2005 · https://doi.org/10.1177/0269881105059253

  • Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines

    Journal of Psychopharmacology · 2000 · 10.1177/026988110001400101

  • Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety.

    PubMed · 1998

  • Unusual interactions of benzodiazepine receptor antagonists

    Nature · 1982 · https://doi.org/10.1038/295436a0

Current projects

    No projects listed.